Clinical Trials Logo

Clinical Trial Summary

A dual POC immunoassay simultaneously detecting non-treponemal and treponemal antibodies was developed for the diagnosis of infections with T. pallidum. The assay is designed for use in resource-limited settings where challenging conditions (such as lack of electricity, running water, or laboratory equipment) commonly exist. We sought to compare performance of the dual-POC assay for diagnosis of yaws infection with that of the RPR and TPHA as reference standards.


Clinical Trial Description

Yaws is an infectious disease caused by Treponema pallidum subspecies pertenue, a bacterium which closely resembles the causative agent of syphilis, and is spread by skin to skin contact. In the field, yaws is diagnosed on the basis of epidemiological context, evocative symptoms and signs and positive serological tests or dark field microscopy. The darkfield microscopy is not easy to perform , hence the interest in serological tests. The serological tests used to confirm yaws are the same as those used to diagnose syphilis. Yaws serologic diagnosis relies on testing for non-treponemal and treponemal antibodies. These antibodies differ markedly with respect to antigenic reactivities and kinetics during the disease process.

Historically screening for yaws has involved the use of nontreponemal tests, such as rapid plasma reagin or venereal disease research laboratory. Positive results of nontreponemal tests of specimens are then confirmed using a more specific treponemal test, such as Treponema pallidum haemagglutination. However, the equipment and personnel requirements for conducting and interpreting these laboratory-tests are rarely available in low-resource settings in developing countries where yaws occurs.

Rapid treponemal tests which detect antibodies to T. pallidum antigen have become popular for the diagnosis of venereal syphilis due to their many advantages. These tests that can be performed outside a laboratory setting with minimal training and using blood collected by a finger prick, which makes them extremely useful in remote areas where laboratories are not available. However, the rapid treponemal tests for syphilis detect treponemal antibodies, which limits their use for interpretation of the disease status since they cannot distinguish between active and past or treated infection.

A combined point-of-care (POC) test which detects both treponemal and non-treponemal antibodies has recently been evaluated for the diagnosis of syphilis, and appears promising for yaws diagnosis. The use of the dual POC test would result in the ability to both screen and confirm the serological status of patients with suspected yaws within 15 minutes and give a better indication of active disease. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01841203
Study type Observational
Source Lihir Medical Centre
Contact
Status Completed
Phase N/A
Start date April 2013
Completion date November 2013

See also
  Status Clinical Trial Phase
Completed NCT01382004 - Single-dose Azithromycin for the Treatment of Yaws Phase 3
Completed NCT03664063 - PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 2
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Completed NCT04453124 - An Accessible Low-cost Plant Treatment for Cutaneous Ulcers Phase 2
Completed NCT01955252 - Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea Phase 3
Active, not recruiting NCT04753788 - Evaluation of a LAMP Assay for T. Pallidum. Pertenue
Active, not recruiting NCT05764876 - Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws) Phase 3
Completed NCT02344628 - Comparison of Two Different Doses of Azithromycin for Treatment of Yaws Phase 3
Completed NCT03683745 - Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Completed NCT02775617 - Azithromycin - Ivermectin Mass Drug Administration for Skin Disease Phase 4
Completed NCT03490123 - Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication Phase 4